Get the Stockscreener App
32.90
0.78%
-0.26
Pre-market:
32.98
0.08
+0.24%
Alkermes Plc stock is traded at $32.90, with a volume of 1.58M.
It is down -0.78% in the last 24 hours and up +4.02% over the past month.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
See More
Previous Close:
$33.16
Open:
$32.81
24h Volume:
1.58M
Relative Volume:
0.77
Market Cap:
$5.43B
Revenue:
$1.51B
Net Income/Loss:
$333.35M
P/E Ratio:
16.87
EPS:
1.95
Net Cash Flow:
$315.22M
1W Performance:
-5.24%
1M Performance:
+4.02%
6M Performance:
+13.25%
1Y Performance:
-8.33%
1-Day Range:
$32.60
$33.74
1-Week Range:
$32.60
$35.15
52-Week Range:
$25.16
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Name
Alkermes Plc
Sector
Phone
00-353-1-772-8000
Address
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
32.90 | 5.48B | 1.51B | 333.35M | 315.22M | 1.95 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.26 | 58.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.56 | 53.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.23 | 49.87B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.41 | 39.57B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
482.42 | 20.39B | 3.13B | 1.27B | 1.12B | 26.39 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Initiated | Truist | Buy |
| Sep-26-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-03-25 | Initiated | Wells Fargo | Overweight |
| Jul-15-25 | Initiated | Goldman | Buy |
| Jun-17-25 | Upgrade | UBS | Neutral → Buy |
| May-28-25 | Initiated | Needham | Buy |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-04-25 | Upgrade | UBS | Sell → Neutral |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Nov-05-24 | Upgrade | Stifel | Hold → Buy |
| Jun-17-24 | Initiated | TD Cowen | Buy |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-20-24 | Downgrade | UBS | Neutral → Sell |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Oct-24-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-17-23 | Initiated | UBS | Neutral |
| Nov-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-14-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-16-22 | Initiated | Piper Sandler | Neutral |
| Apr-22-22 | Resumed | Goldman | Buy |
| Apr-20-22 | Initiated | Goldman | Buy |
| Jan-27-22 | Upgrade | Cantor Fitzgerald | Hold → Overweight |
| Dec-01-21 | Initiated | Citigroup | Neutral |
| Oct-07-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-02-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Oct-15-20 | Upgrade | Mizuho | Neutral → Buy |
| Jul-30-20 | Downgrade | Goldman | Neutral → Sell |
| Feb-14-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-14-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-14-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Jan-31-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jul-15-19 | Upgrade | Goldman | Sell → Neutral |
| May-31-19 | Initiated | H.C. Wainwright | Neutral |
| May-01-19 | Downgrade | Citigroup | Buy → Neutral |
| Dec-19-18 | Downgrade | Goldman | Neutral → Sell |
| Dec-14-18 | Initiated | Wolfe Research | Underperform |
| Dec-13-18 | Downgrade | Credit Suisse | Outperform → Underperform |
| Nov-05-18 | Initiated | Piper Jaffray | Neutral |
| Aug-07-18 | Initiated | Stifel | Hold |
| Jun-21-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-06-18 | Initiated | B. Riley FBR, Inc. | Buy |
| May-16-18 | Upgrade | Citigroup | Neutral → Buy |
| May-11-18 | Initiated | BofA/Merrill | Buy |
View All
Alkermes Plc Stock (ALKS) Latest News
Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? - Finviz
Ireland's Alkermes plc buys Avadel Pharmaceuticals plc - ALCHEMPro
Avadel Pharmaceuticals plc acquired by Alkermes plc - Arthur Cox LLP
What analysts say about Alkermes plc stockTrade Performance Summary & High Conviction Buy Zone Picks - mfd.ru
Will Alkermes plc outperform its industry peersJuly 2025 Reactions & Community Driven Trade Alerts - mfd.ru
Sentiment Review: Can Alkermes plc stock beat market expectations this quarterQuarterly Portfolio Review & Free AI Powered Buy and Sell Recommendations - mfd.ru
Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat
Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals - CHEManager
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales - Finviz
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates - Finviz
Is Alkermes plc a top pick in the sectorCEO Change & Weekly Stock Performance Updates - mfd.ru
Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market - marketscreener.com
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - BioSpace
Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market - TradingView
Alkermes PLC has successfully completed the acquisition of Avadel Pharmaceuticals plc. - Bitget
Alkermes Acquires Avadel Pharmaceuticals - Contract Pharma
Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement - marketscreener.com
Alkermes Completes Acquisition and Delisting of Avadel Pharmaceuticals - TipRanks
Alkermes Acquires Avadel to Expand Product Portfolio - Intellectia AI
Alkermes Signs Credit Agreement With JPMorgan Chase and BofA Securities - TradingView
Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans - Stock Titan
Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio - Sleep Review
Understanding the Setup: (ALKS) and Scalable Risk - Stock Traders Daily
Alkermes to report fourth quarter and year-end financial results on Feb. 25, 2026 - MSN
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 - Business Wire
Alkermes earnings up next as sleep strategy takes shape By Investing.com - Investing.com Canada
Alkermes earnings up next as sleep strategy takes shape - Investing.com Nigeria
Can Alkermes plc stock surprise with earnings upsideEarnings Growth Summary & Stock Portfolio Risk Management - mfd.ru
Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes - TipRanks
Alkermes (ALKS) Set to Finalize Acquisition of Avadel Pharmaceuticals - GuruFocus
Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc - Quiver Quantitative
Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing - The Manila Times
Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11 - Stock Titan
Alkermes Increases Offer for Avadel Acquisition - MSN
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz
Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
History Review: Will Alkermes plc outperform its industry peersJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn
Allianz Asset Management GmbH Acquires 511,702 Shares of Alkermes plc $ALKS - MarketBeat
KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Finviz
Stop Loss: Is Alkermes plc benefiting from interest rate changesPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Alkermes (ALKS) Projected to Post Earnings on Wednesday - MarketBeat
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
Alkermes (NASDAQ:ALKS) Director Sells $2,115,684.00 in Stock - MarketBeat
Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares - MarketBeat
Alkermes plc (ALKS) Stock Analysis: Navigating a 29% Potential Upside in the Biopharmaceutical Sector - DirectorsTalk Interviews
Alkermes Plc Stock (ALKS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):